Consensus Sotera Health Company

Equities

SHC

US83601L1026

Market Closed - Nasdaq 04:00:00 2024-04-26 pm EDT 5-day change 1st Jan Change
11.4 USD +0.71% Intraday chart for Sotera Health Company +4.11% -32.34%

Evolution of the average Target Price on Sotera Health Company

Price target over the last 5 years

History of analyst recommendation changes

8dd52ee4204eae2c02a535f065a18f7.XtqF5Op0PSqzEY7VAgSpTZmckQllEtth27cTKDORuJg.ZqC8qoMFT0_Lf_29c3HMBs75_GQXP4MPovxnbGn_2cwE6tS0owd8G_9j1w~aa72f396649d0fd216f02e31b6f1e3e2
Citigroup Upgrades Sotera Health to Buy From Neutral, Cuts Price Target to $16 From $18 MT
Sotera Health Shares Rise Following Jefferies Upgrade MT
Jefferies Upgrades Sotera Health to Buy From Hold, Price Target is $15.50 MT
Barclays Adjusts Price Target on Sotera Health to $17 From $15, Maintains Overweight Rating MT
RBC Cuts Price Target on Sotera Health to $20 From $22, Keeps Outperform Rating MT
KeyBanc Adjusts Price Target on Sotera Health to $23 From $24, Maintains Overweight Rating MT
RBC Raises Price Target on Sotera Health to $22 From $18, Keeps Outperform Rating MT
Sotera Health Upgraded by KeyBanc to Overweight From Sector Weight Post Settlement of Ethylene Oxide Claims, Price Target Set at $24 MT
Barclays Adjusts Price Target on Sotera Health to $20 From $21, Maintains Overweight Rating MT
RBC Cuts Price Target on Sotera Health to $18 From $19, Maintains Outperform Rating MT
Barclays Adjusts Sotera Health Price Target to $21 From $22, Maintains Overweight Rating MT
RBC Boosts Price Target on Sotera Health to $19 From $8, Maintains Outperform Rating MT
JPMorgan Upgrades Sotera Health to Neutral From Underweight, Adjusts Price Target to $18 From $6 MT
Barclays Upgrades Sotera Health to Overweight From Underweight, Adjusts Price Target to $22 From $6 MT
Wolfe Research Upgrades Sotera Health to Outperform From Peer Perform, Price Target is $25 MT
Goldman Sachs Adjusts Sotera Health's Price Target to $8 From $9, Keeps Neutral Rating MT
Barclays Downgrades Sotera Health Company to Underweight From Equalweight, Lowers Price Target to $6 From $7 MT
Barclays Trims Sotera Health Company's Price Target to $7 From $8, Maintains Equalweight Rating MT
Citigroup Lowers Sotera Health Company's Price Target to $7 From $9, Maintains Neutral Rating MT
Jefferies Lowers Sotera Health Company's Price Target to $7 From $21, Maintains Hold Rating MT
JPMorgan Lowers Sotera Health Company's Price Target to $6 From $9, Maintains Underweight Rating MT
RBC Cuts Price Target on Sotera Health to $8 From $25, Maintains Outperform Rating MT
Barclays Adjusts Sotera Health's Price Target to $8 From $22, Keeps Equalweight Rating MT
Citigroup Downgrades Sotera Health to Neutral From Buy; Price Target is $9 MT
Capitulation ahead? Our Logo
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
11.4 USD
Average target price
16.75 USD
Spread / Average Target
+46.93%
High Price Target
20 USD
Spread / Highest target
+75.44%
Low Price Target
14 USD
Spread / Lowest Target
+22.81%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Sotera Health Company

Citigroup
Jefferies & Co.
Barclays
RBC Capital Markets
KeyBanc Capital Markets
JPMorgan Chase
Wolfe Research
Goldman Sachs
Credit Suisse
Baird
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
  1. Stock Market
  2. Equities
  3. SHC Stock
  4. Consensus Sotera Health Company